EUCTR2009-015606-19-LT进行中（未招募）不适用
A Phase III Randomized Double-blind, Placebo-controlled Multicenter Study of Icatibant for Subcutaneous Injection in Patients with Acute Attacks of Hereditary Angioedema (HAE) - FAST-3
Jerini US Inc0 个研究点目标入组 88 人开始时间: 2010年3月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each patient must meet the following criteria to be enrolled in this study:
- •1) The patient is =18 years old at the time of informed consent.
- •2) The patient has a documented diagnosis of HAE type I or II. The diagnosis will be confirmed either by documented decreased C4 levels and/or immunogenic or functional C1-INH deficiency results (<50% of normal levels) consistent with HAE types I and II or by medical history. Inclusion will be permitted initially based on medical history alone only if a clear diagnosis has been made using all of the following criteria:
- •a. Family history
- •b. Characteristic attack manifestations, recurrent attacks
- •c. Historical functional C1-INH (<50% of normal levels)
- •d. Exclusion of other forms of angioedema including acquired angioedema based on normal C1q levels at time of screening.
- •e. Subsequent confirmation of the diagnosis is to be made by C1-INH level and function, and C1q and C4 results measured in a central laboratory. If there are any discrepancies between the local laboratory results and medical history, the patient can only be included in the efficacy analysis if diagnosis of HAE has been clearly confirmed clinically and a rationale for the functional level of C1-INH =50% of normal can be given; these specific cases are to be discussed with the Sponsor prior to treatment. If there is a discrepancy between C4 and C1-INH levels, the results will be reviewed by the sponsor but C1-INH levels will be used to determine eligibility of the patient.
- •3) The current HAE attack must be in the cutaneous, abdominal and/or laryngeal (inclusive of laryngeal and pharyngeal) areas.
- •4) Cutaneous or abdominal HAE attacks must be moderate to very severe as determined by investigator global assessment at pretreatment assessments.
- •5) The patient must report at least 1 VAS score =30mm.
- •6) The patient commences treatment within 6 hours of the attack becoming at least mild (laryngeal) or moderate (non-laryngeal) in severity, but not more than 12 hours after the onset of the attack.
- •7) The patient must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient.
- •8) Women of childbearing potential must have a negative urine pregnancy test and must use appropriate methods to prevent pregnancy during their participation in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who meet any of the following criteria will be excluded from the study:
- •1) The patient has a diagnosis of angioedema other than HAE (non-hereditary angioedema, eg, acquired angioedema).
- •2) The patient has received previous treatment with icatibant.
- •3) The patient has participated in a clinical trial and has received treatment with another investigational medicinal product within the past 30 days.
- •4) The patient has received treatment with any pain medication since the onset of the current angioedema attack.
- •5) The patient has received replacement therapy (fresh frozen plasma [FFP], C1-INH products) less than 5 days (120 hours) from the onset of the current angioedema attack.
- •6) The patient is receiving treatment with angiotensin converting enzyme (ACE) inhibitors.
- •7) The patient has evidence of coronary artery disease based on medical history at the Screening examination or at pretreatment; eg, unstable angina pectoris or severe coronary heart disease and congestive heart failure, that in the Investigator’s judgment would be a contraindication for participation in the trial. (New York Heart Association [NYHA] class 3 and 4).
- •8) The patient has a serious concomitant illness or condition that, in the opinion of the Investigator, would be a contraindication for participation in the trial.
- •9) The patient is pregnant or breastfeeding.
- •10) The patient is unable to understand the nature, scope, and possible consequences of the protocol, or is unlikely to comply with the protocol assessments, unable to return for follow up visits, or unlikely to complete the study for any reason.
研究者
相似试验
进行中（未招募）
1 期
A Phase III Randomized Double-blind, Placebo-controlled Multicenter Study of Icatibant for Subcutaneous Injection in Patients with Acute Attacks of Hereditary Angioedema (HAE) - FAST-3Hereditary angioedema (HAE) in adults patients with C1-esterase inhibitor deficiencyMedDRA version: 12.0Level: LLTClassification code 10019860Term: Hereditary angioedemaEUCTR2009-015606-19-HUJerini US Inc88
进行中（未招募）
1 期
Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Ulcerative Colitis, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)(FIGARO UC 301).lcerative colitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2017-000599-27-DEShire Human Genetic Therapies, Inc.825
已完成
3 期
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 301)Ulcerative ColitisNL-OMON50514Shire29
进行中（未招募）
1 期
Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Ulcerative Colitis, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)(FIGARO UC 301).lcerative colitisMedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856EUCTR2017-000599-27-GBShire Human Genetic Therapies, Inc.825
进行中（未招募）
1 期
Research study to determine whether an investigational drug, SHP647, is safe and effective in the treatment of moderate to severe Ulcerative Colitis, compared with placebo (dummy treatment) – using a randomised and blinded study design (investigator and patients are not aware whether they receive study drug or placebo)(FIGARO UC 301).EUCTR2017-000599-27-ATShire Human Genetic Therapies, Inc.825